New medicines are approved. Biosimilars launch. Payers revise policies. HCPCS codes change. Assistance programs open, close or move. MedicineCostHelp is designed as a maintained resource—not a one-time database dump.
All 442 medicine guides now include direct paths for prior authorization, denial, preferred-product, site-of-care, high-cost and post-authorization claim problems, plus the privacy-first Coverage Action Plan. The new links are normal crawlable HTML and do not collect patient information.
Build a next-step plan → · Browse access playbooks →The v4.0 launch-readiness gates completed GREEN. The next operating phase focuses on source freshness, measured search demand, useful patient actions and controlled care-team distribution—not arbitrary page-count growth.
Care-team resource → · Share toolkit →New guides cover medical-necessity and experimental denials, renewal and plan-year resets, dose changes, peer-to-peer review, letters of medical necessity, corrected claims, specialty-pharmacy sourcing, white/brown bagging, site-of-care exceptions and authorization/claim mismatches.
Open the Learn library →New playbooks now cover employer-plan documents, self-funded plans, COBRA, Marketplace enrollment after job loss, mid-treatment insurance changes, continuity of care, directory errors, EOB/bill mismatches, hospital financial assistance and price transparency, Good Faith Estimate disputes, QMB billing protection, Medicare assignment, appeal records, urgent reviews and authorized representatives.
Open the Learn library →New playbooks now cover claim-vs-authorization denials, internal/external appeals, deductibles and coinsurance, allowed amounts, network exceptions, hospital outpatient cost sharing, No Surprises protections, self-pay Good Faith Estimates, Medigap, Medicare Savings Programs, coordination of benefits, Medicare Advantage Part B step therapy and clinical-trial costs.
Open the Learn library →The action plan now adds state-aware Medicaid routing, patient/care-team modes, questions to ask and a copyable/printable handoff. Care teams also get a public QR handout and copyable patient introduction.
Build a plan → · Share toolkit →Primary IgA nephropathy · weekly SC biologic.
Open guide →Chronic hepatitis delta · SC specialty therapy.
Open guide →Achondroplasia · once-weekly SC injection.
Open guide →Aetna revised CPB 0804 on August 21. MedicineCostHelp flagged the change for human review; the denosumab guidance was then updated to reflect Ponlimsi's addition to the Prolia biosimilar pathway and Aetna's new site-of-care language. Public guidance was not rewritten automatically.
Open the denosumab coverage family →FDA-approved July 24, 2026 for neovascular (wet) age-related macular degeneration. We added a new-to-market coverage guide that does not pretend payer preference or permanent coding has already caught up.
Lytenava coverage guide →The first FDA-approved interchangeable IV biosimilar to Simponi Aria. Its current FDA indication is narrower than the reference product, so our engine now supports product-specific indication filtering.
Immgolis Intri coverage guide →Added the July 31 FDA expansion into PSMA-positive metastatic androgen pathway modulation-naïve/sensitive prostate cancer in combination with ARPI therapy.
Pluvicto coverage guide →Added the 2026 Stage 2 age expansion and the new pediatric Stage 3 type 1 diabetes indication so the coverage navigator no longer assumes the older label.
Tzield coverage guide →Updated the gene-therapy pathway after FDA expanded sickle cell disease and transfusion-dependent beta-thalassemia use to eligible patients age 2 years and older.
Casgevy coverage guide →A changed fingerprint is a reason to review a source—not permission for software to reinterpret an insurance policy. Consequential coverage, coding and patient-guidance changes require human review before the public site changes.
Send us the page, what looks wrong, and the current official source if you have it. Do not send patient information.
Contact & corrections →Machine-readable: updates-data.json · RSS feed